These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9114912)

  • 21. Clinical and biological evaluation of dilevalol vasodilating properties in mild to moderate hypertension.
    Drici MD; Candito M; Ferrari E; Jacomet Y; Morand P; Lapalus P
    Int J Clin Pharmacol Ther Toxicol; 1991 Sep; 29(9):361-5. PubMed ID: 1937998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrinsic beta-sympathomimetic activity of dilevalol, R, R-isomer of labetalol.
    Matsunaga K; Nakamura K; Ueda M
    J Pharmacobiodyn; 1985 Sep; 8(9):785-7. PubMed ID: 2868089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.
    Grove A; Lipworth BJ
    Thorax; 1996 Jan; 51(1):54-8. PubMed ID: 8658370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.
    McCaffrey PM; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects.
    Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
    J Clin Pharmacol; 1989 Jul; 29(7):635-42. PubMed ID: 2668352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW; Laugerotte A; Wright JM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.
    Tomlinson B; Renondin JC; Graham BR; Prichard BN
    Eur J Clin Pharmacol; 1991; 41(1):1-3. PubMed ID: 1685992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of beta-, alpha- and combined beta- plus alpha-adrenoceptor blocking agents in stress-induced increase in arterial blood pressure.
    Pandhi P; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):297-300. PubMed ID: 2887519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S12-7. PubMed ID: 2464093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of beta 2-receptor stimulation in the peripheral vascular actions of the antihypertensive dilevalol.
    Watkins RW; Sybertz EJ; Cook J; Pula K; Cedeno K; Tedesco RP; McLeod R
    Arch Int Pharmacodyn Ther; 1989; 302():158-73. PubMed ID: 2576892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dilevalol, a beta-adrenoceptor antagonist with intrinsic sympathetic activity in asthmatic patients.
    Hedner J; Ullman A; Lemne C; Svedmyr N
    Pulm Pharmacol; 1989; 2(3):155-9. PubMed ID: 2577692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
    Pringle TH; O'Connor PC; McNeill AJ; Finch MB; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1986 Mar; 21(3):249-58. PubMed ID: 2870732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of dilevalol on forearm circulation in essential hypertension.
    Giannattasio C; Cleroux J; Seravalle G; Grassi G; Mancia G; Zanchetti A
    Am J Cardiol; 1989 Jun; 63(19):21I-24I. PubMed ID: 2567111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
    Chrisp P; Goa KL
    Drugs; 1990 Feb; 39(2):234-63. PubMed ID: 2184002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats.
    Drew GM; Hilditch A; Levy GP
    Clin Exp Hypertens (1978); 1979; 1(5):597-611. PubMed ID: 42517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and efficacy of once-daily dilevalol in patients with mild hypertension: a placebo-controlled study.
    Soberman J; Greenberg S; Frishman W
    J Clin Hypertens; 1987 Sep; 3(3):271-7. PubMed ID: 3312501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dilevalol in the anesthetized pig with a partially occluded coronary artery.
    den Boer MO; Sassen LM; van der Giessen WJ; Saxena PR; Verdouw PD
    Cardiovasc Drugs Ther; 1990 Dec; 4(6):1461-5. PubMed ID: 1981977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects.
    Schafers RF; Elliott HL; Howie CA; Reid JL
    Br J Clin Pharmacol; 1991 Nov; 32(5):599-604. PubMed ID: 1683249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.